AtriCure and Century Medical of Japan have announced the extension and expansion of their multi-year agreement in which Century Medical will distribute AtriCure’s surgical ablation technologies to hospitals in Japan.
The new agreement provides Century Medical with exclusive rights to market the AtriCure product lines, including future sales of the AtriClip Left Atrial Appendage Exclusion System once formal approval processes are completed by Century Medical. The AtriClip is one of the fastest growing segments of the overall AtriCure portfolio worldwide. This agreement marks the first time the products will be available in Japan, according to a press release.
“We are very excited about solidifying and expanding a long-term relationship with a team so talented, experienced and knowledgeable in our products,” said Michael Carrel, president and CEO of AtriCure. “This agreement sets a strong foundation in the Japanese market for many years to come.”
According to the agreement, Century Medical will be the exclusive distributor of AtriCure devices for Japan until 2019, with minimum revenue commitments set forth over the next three years.
“We are pleased to continue our partnership with AtriCure, and provide the people of Japan life-changing treatment tools for use in soft tissue ablation. With the opportunity to use AtriCure devices increasing in Japan, our partnership has the potential to benefit hundreds of thousands of people,” said Akira Hoshino, president and CEO of Century Medical.